Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
106M
-
Number of holders
-
190
-
Total 13F shares, excl. options
-
105M
-
Shares change
-
+6.55M
-
Total reported value, excl. options
-
$2.32B
-
Value change
-
+$130M
-
Put/Call ratio
-
0.57
-
Number of buys
-
98
-
Number of sells
-
-100
-
Price
-
$22.00
Significant Holders of Edgewise Therapeutics, Inc. - Common Stock (EWTX) as of Q1 2025
253 filings reported holding EWTX - Edgewise Therapeutics, Inc. - Common Stock as of Q1 2025.
Edgewise Therapeutics, Inc. - Common Stock (EWTX) has 190 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 105M shares
of 106M outstanding shares and own 99.49% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (15M shares), RA CAPITAL MANAGEMENT, L.P. (8.91M shares), PERCEPTIVE ADVISORS LLC (6.55M shares), BlackRock, Inc. (6.49M shares), BAKER BROS. ADVISORS LP (6.16M shares), Novo Holdings A/S (5.35M shares), JANUS HENDERSON GROUP PLC (5.28M shares), Paradigm Biocapital Advisors LP (4.39M shares), VANGUARD GROUP INC (4.29M shares), and Cormorant Asset Management, LP (4.1M shares).
This table shows the top 190 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.